Clinical trial
Optimized Chemotherapy Followed by Maintenance With Bevacizumab With or Without…
NCT00265824 · GERCOR - Multidisciplinary Oncology Cooperative Group, Other · Completed
Key facts
| NCT number | NCT00265824 |
|---|---|
| Title | Optimized Chemotherapy Followed by Maintenance With Bevacizumab With or Without Erlotinib in Treating Patients With Metastatic Colorectal Cancer That Cannot be Removed by Surgery (DREAM) |
| Official title | Phase III Study of an Optimized Chemotherapy Followed by Maintenance With Bevacizumab Strategy With or Without Erlotinib in Unresectable Metastatic Colorectal Cancer. DREAM OPTIMOX 3. C04-2 |
| Acronym | DREAM |
| Lead sponsor | GERCOR - Multidisciplinary Oncology Cooperative Group, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Colorectal Cancer |
| Intervention type | Drug |
| Interventions | bevacizumab, erlotinib |
| Enrollment | 700 |
| Start date | May 1, 2005 |
| Primary completion | Mar 1, 2012 |
| First posted | Dec 15, 2005 |
| Last update posted | Dec 11, 2015 |
| Countries | Austria, Canada, France |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: